Home / Treatments / Diabetic Medication
Diabetic Medication denials: what the review data shows
Independent reviewers have decided 288 published cases where an insurer denied Diabetic Medication — and they overturned the insurer 74.7% of the time. A denial for Diabetic Medication is a starting position, not a final answer.
Published decisions
288
2001–2026
Overturned
74.7%
215 denials reversed
Conditions behind diabetic medication denials
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Diabetes | 244 | 75.8% |
| Type 2 Diabetes | 10 | 80% |
| Obesity | 5 | 80% |
| Hormone Abnormality | 4 | 75% |
| Hypertension | 3 | 66.7% |
| Ovarian Cyst | 3 | 66.7% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 267 | 76.8% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 21 | 47.6% |
Typical time to a decision
13 days
Most land between 5 and 21 days
Handled as urgent
43.1%
Expedited when a delay would cause harm
Recent direction
Falling
81.9% → 75.1% overturned, last three years
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Ozempic. Obesity is defined as having a body mass index (BMI) over 30 kg/m2 and is associated with an increased risk of diabetes, hypertension, hyperlipidemia, stroke, and malignant tumors. Obesity is a chronic disease for which medication-assisted weight loss is indicated in conjunction with lifestyle therapy for patients who are at risk for developing type 2 diabetes mellitus. The STEP 8 clinical trial compared the efficacy and safety profile of semaglutide versus liraglutide for the treatment of patients with overweight or obesity. The authors found that semaglutide resulted in significantly greater weight loss than liraglutide and greater improvements in several cardiometabolic risk factors.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for G-Voke HypoPen. In this case, the patient has insulin-dependent diabetes complicated by gastroparesis, a delay in gastric emptying without any obstruction in the gastric outlet. It is caused by autonomic neuropathy and is often associated with an increased risk of hypoglycemia in diabetic patients. A researcher explains, “Hypoglycemia is a common problem in patients with diabetes, and often limits those trying to achieve tight glucose control. Achieving optimal glucose control is necessary to prevent microvascular complications. Hypoglycemia can cause mild disturbances to daily life, but in severe cases can be fatal.” To prevent medical sequelae of severe hypoglycemic emergencies, prompt and reliable rescue intervention is critically important.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Rybelsus tablet 14 mg. Prediabetes is a precursor to type 2 diabetes, a disease highly associated with microvascular and macrovascular disease. Patients with prediabetes have a higher average sugar than normal but not as high as those with diabetes. For patients with prediabetes, the American Association of Clinical Endocrinology (AACE) recommends lifestyle changes. Medications for obesity are recommended for patients with a body mass index (BMI) over 27 kg/m2 such as phentermine/topiramate ER, liraglutide, or weekly semaglutide.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Mounjaro. Diabetes mellitus is a common, albeit potentially devastating, medical condition that has increased in prevalence over the past few decades to constitute a major public health challenge in the twenty-first century. The mortality rate for patients with diabetes is one and a half times higher than for individuals without diabetes. Tirzepatide (brand name Mounjaro), a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus, along with diet and exercise, based on clinical data demonstrating that tirzepatide is superior to placebo in improving hemoglobin (Hb) A1C levels.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Diabetic Medicationwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.